Effect of Mass Deworming on Child Growth

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-08-31

Study Completion Date

2003-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to determine whether periodical mass deworming improves growth in children below six years of age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many children in developing countries get slowed growth because of heavy loads of intestinal helminths. Quite often treatment is not sought because there may not be any obvious symptoms. Slowed growth may manifest as low weight for age or low height for age.

The objective of the study was to estimate the effectiveness of the delivery of an anthelmintic drug through a community child health program on the weight gain of preschool aged children.

Design: This was a cluster randomized controlled trial in 48 parishes in Eastern Uganda. All 48 parishes were participating in a new program for child health; 24 were randomly assigned to offer to children an additional service of anthelmintic treatment. The intervention was 400 mg of albendazole added to the standard services at child days over a 3 years period. All children were offered the drug and the main outcome measure was weight gain.

Results: A total of 27,995 children were recruited into the 2 arms of the study with 14,940 in the treatment arm and 13,055 in the control arm. The intervention arm got an increase in weight gain of about 10% (166 grams per child per year (CI: 16-316) above expected weight gain when treatment was taken twice a year and an increase of 5% when treatment was received approximately annually.

Conclusion: The inclusion of deworming in regularly scheduled health services appears practical and capable of increasing child growth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Weight for Age in Preschool Children

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

underweight preschool mass deworming

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albendazole 400 mg, given 6 monthly

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children 1-6 years

Exclusion Criteria

\-

Minimum Eligible Age

1 Year

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph K Konde-Lule, MD DPH MSc

Role: PRINCIPAL_INVESTIGATOR

Makerere University

John F Mutumba, MBChB, MSc

Role: STUDY_CHAIR

Ministry of Health, Uganda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

48 parishes in Eastern Uganda

Kampala, , Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Uganda

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P05267

Identifier Type: -

Identifier Source: org_study_id